Medline ® Abstract for Reference 53
of 'Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor'
Miller V, Hirsh V, Cadranel J, et al. Phase IIB/III double-blind randomized trial of afatinib + best supportive care versus placebo + best supportive care in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinb or gefitinib (LUX-1) (abstract). European Society of Medical Oncology 2014 meeting.
no abstract available